scholarly journals Genistein Loaded Nanofibers Protect Spinal Cord Tissue Following Experimental Injury in Rats

2018 ◽  
Author(s):  
Mohamed Ismail ◽  
Sara Ibrahim ◽  
Azza Elamir ◽  
Amira M. Elrafei ◽  
Nageh Allam ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Drug Delivery System ◽  
Delivery System ◽  
Enhanced Recovery ◽  
Therapeutic Drug ◽  
Control Group ◽  
Spinal Cord Tissue ◽  
Injured Spinal Cord ◽  
Cord Injury

Implantable drug-delivery systems provide new means for achieving therapeutic drug concentration over a prolonged time to achieve better tissue protection and enhanced recovery. The hypothesis of the current study was to test the antioxidant and anti-inflammatory effects of genistein and nanofibers on the spinal cord tissue following experimental spinal cord injury (SCI). Rats were treated post SCI with genistein loaded on chitosan/polyvinyl alcohol (CS/PVA) nanofibers as an implantable drug-delivery system. SCI caused marked oxidative damage and inflammation as evident by the reduction in the super oxide dismutase (SOD) activity and the level of interleukin-10 (IL-10) in injured spinal cord tissue, as well as, the significant increase in the levels of nitric oxide (NO), malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α). Treatment of rats post SCI with genistein and CS/PVA nanofibers improved most of the above mentioned biochemical parameters and shifted them toward the control group values. Genistein induced an increase in the activity of SOD and the level of IL-10, while causing a decrease in the levels of NO, MDA and TNF-α in injured spinal cord tissue. Genistein and CS/PVA nanofibers provide a novel combination for treating inflammatory nervous tissue conditions, especially when combined as an implantable drug-delivery system.

scholarly journals Genistein Loaded Nanofibers Protect Spinal Cord Tissue Following Experimental Injury in Rats

Biomedicines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 96 ◽  
Author(s):  
Mohamed Ismail ◽  
Sara Ibrahim ◽  
Azza El-Amir ◽  
Amira EL-Rafei ◽  
Nageh Allam ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Drug Delivery System ◽  
Delivery System ◽  
Therapeutic Drug ◽  
Control Group ◽  
Spinal Cord Tissue ◽  
Injured Spinal Cord ◽  
Tnf Α ◽  
Cord Injury

Innovative drug-delivery systems offer a unique approach to effectively provide therapeutic drug dose over the needed time to achieve better tissue protection and enhanced recovery. The hypothesis of the current study was to test the antioxidant and anti-inflammatory effects of genistein and nanofibers on the spinal cord tissue following experimental spinal cord injury (SCI). Rats were treated post SCI with genistein that is loaded on chitosan/polyvinyl alcohol (CS/PVA) nanofibers as an implantable drug-delivery system. SCI caused marked oxidative damage and inflammation, as is evident by the reduction in the super oxide dismutase (SOD) activity and the level of interleukin-10 (IL-10) in injured spinal cord tissue, as well as the significant increase in the levels of nitric oxide (NO), malondialdehyde (MDA), and tumor necrosis factor-alpha (TNF-α). Treatment of rats post SCI with genistein and CS/PVA nanofibers improved most of the above-mentioned biochemical parameters and shifted them toward the control group values. Genistein induced an increase in the activity of SOD and the level of IL-10, while causing a decrease in NO, MDA, and TNF-α in injured spinal cord tissue. Genistein and CS/PVA nanofibers provide a novel combination for treating inflammatory nervous tissue conditions, especially when combined as an implantable drug-delivery system.

scholarly journals Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Guodong Sun ◽  
Shenghui Zeng ◽  
Xu Liu ◽  
Haishan Shi ◽  
Renwen Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Mesoporous Silica ◽  
Drug Delivery System ◽  
Delivery System ◽  
Central Component ◽  
High Dose ◽  
Interleukin 17 ◽  
Cord Injury

Abstract Acute inflammation is a central component in the progression of spinal cord injury (SCI). Anti-inflammatory drugs used in the clinic are often administered systemically at high doses, which can paradoxically increase inflammation and result in drug toxicity. A cluster-like mesoporous silica/arctigenin/CAQK composite (MSN-FC@ARC-G) drug delivery system was designed to avoid systemic side effects of high-dose therapy by enabling site-specific drug delivery to the spinal cord. In this nanosystem, mesoporous silica was modified with the FITC fluorescent molecule and CAQK peptides that target brain injury and SCI sites. The size of the nanocarrier was kept at approximately 100 nm to enable penetration of the blood–brain barrier. Arctigenin, a Chinese herbal medicine, was loaded into the nanosystem to reduce inflammation. The in vivo results showed that MSN-FC@ARC-G could attenuate inflammation at the injury site. Behavior and morphology experiments suggested that MSN-FC@ARC-G could diminish local microenvironment damage, especially reducing the expression of interleukin-17 (IL-17) and IL-17-related inflammatory factors, inhibiting the activation of astrocytes, thus protecting neurons and accelerating the recovery of SCI. Our study demonstrated that this novel, silica-based drug delivery system has promising potential for clinical application in SCI therapy.

An In Situ Gelling Drug Delivery System for Improved Recovery after Spinal Cord Injury

2016 ◽  
Vol 5 (12) ◽  
pp. 1513-1521 ◽  
Author(s):  
Dongfei Liu ◽  
Tao Jiang ◽  
Weihua Cai ◽  
Jian Chen ◽  
Hongbo Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Drug Delivery System ◽  
Delivery System ◽  
Cord Injury ◽  
In Situ Gelling

scholarly journals TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yan Lin ◽  
Yujie Wan ◽  
Xingjie Du ◽  
Jian Li ◽  
Jun Wei ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Drug Delivery System ◽  
Delivery System ◽  
Target Drug Delivery ◽  
Target Drug ◽  
Cord Injury ◽  
Target Drug Delivery System ◽  
Targeting Ability

Abstract Background Spinal Cord injury (SCI) is a kind of severe traumatic disease. The inflammatory response is a significant feature after SCI. Tetramethylpyrazine (TMP), a perennial herb of umbelliferae, is an alkaloid extracted from ligustici. TMP can inhibit the production of nitric oxide and reduce the inflammatory response in peripheral tissues. It can be seen that the therapeutic effect of TMP on SCI is worthy of affirmation. TMP has defects such as short half-life and poor water-solubility. In addition, the commonly used dosage forms of TMP include tablets, dropping pills, injections, etc., and its tissue and organ targeting is still a difficult problem to solve. To improve the solubility and targeting of TMP, here, we developed a nanotechnology-based drug delivery system, TMP-loaded nanoparticles modified with HIV trans-activator of transcription (TAT-TMP-NPs). Results The nanoparticles prepared in this study has integrated structure. The hemolysis rate of each group is less than 5%, indicating that the target drug delivery system has good safety. The results of in vivo pharmacokinetic studies show that TAT-TMP-NPs improves the bioavailability of TMP. The quantitative results of drug distribution in vivo show that TAT-TMP-NPs is more distributed in spinal cord tissue and had higher tissue targeting ability compared with other treatment groups. Conclusions The target drug delivery system can overcome the defect of low solubility of TMP, achieve the targeting ability, and show the further clinical application prospect.

Pseudo-branched polyester copolymer: an efficient drug delivery system to treat cancer

2020 ◽  
Vol 8 (6) ◽  
pp. 1592-1603
Author(s):  
Zachary Shaw ◽  
Arth Patel ◽  
Thai Butcher ◽  
Tuhina Banerjee ◽  
Ren Bean ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Drug Delivery System ◽  
Delivery System ◽  
Diagnosis And Treatment ◽  
Therapeutic Drug

New aliphatic pseudo-branched polyester copolymers are synthesized from diethylmalonate. The formulated nanomedicine successfully encapsulates therapeutic drug in higher dosage and deliver specifically to cancer cells for diagnosis and treatment.

Presence and significance of CD-95 (Fas/APO1) expression after spinal cord injury

2001 ◽  
Vol 94 (2) ◽  
pp. 257-264 ◽  
Author(s):  
Mercedes Zurita ◽  
Jesús Vaquero ◽  
Isabel Zurita
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
White Matter ◽  
Gray Matter ◽  
Spinal Cord Tissue ◽  
Injured Spinal Cord ◽  
Content Type ◽  
Cord Injury ◽  
Positive Immunostaining ◽  
Fine Print

Object. A glycoprotein, CD95 (Fas/APO1) is widely considered to be implicated in the development of apoptosis in a number of tissues. Based on the hypothesis that apoptosis is related to cell death after spinal cord injury (SCI), the authors studied the presence and distribution of CD95 (Fas/APO1)-positive cells in injured spinal cord tissue for the purpose of determining the significance of this protein during the early phases of SCI. Methods. The presence and distribution of cells showing positive immunostaining for CD95 (Fas/APO1) were studied 1, 4, 8, 24, 48, and 72 hours and 1, 2, and 4 weeks after induction of experimental SCI in rats. Studies were conducted using a monoclonal antibody to the CD95 (Fas/APO1) protein. Positivity for CD95 (Fas/APO1) was observed in apoptotic cells, mainly in the gray matter, 1 hour after trauma, and the number of immunostained cells increased for the first 8 hours, at which time the protein was expressed in both gray and white matter. From 24 to 72 hours postinjury, the number of immunostained cells decreased in the gray matter, but increased in the white matter. From then on, there were fewer CD95 (Fas/APO1)-positive cells, but some cells in the white matter still exhibited positive immunostaining 1 and 2 weeks after injury. At 4 weeks, there remained no CD95 (Fas/APO1)-positive cells in injured spinal cord. Conclusions. These findings indicate that CD95 (Fas/APO1) is expressed after SCI, suggesting a role for this protein in the development of apoptosis after trauma and the possibility of a new therapeutic approach to SCI based on blocking the CD95 (Fas/APO1) system.

Sign in / Sign up

Export Citation Format

Share Document